The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Viral infections that mothers catch during pregnancy still cause much illness in babies either in the womb, or after birth. One of these infections called CMV causes more babies to be born with malformation in Australia than any other infection, and is second only to cerebral palsy as a cause of serious problems in babies. Our studies are examining CMV in mothers and babies, leading to better diagnostic tests, researching use of existing and new antiviral drugs to reduce infection in these mothe ....Viral infections that mothers catch during pregnancy still cause much illness in babies either in the womb, or after birth. One of these infections called CMV causes more babies to be born with malformation in Australia than any other infection, and is second only to cerebral palsy as a cause of serious problems in babies. Our studies are examining CMV in mothers and babies, leading to better diagnostic tests, researching use of existing and new antiviral drugs to reduce infection in these mothers and babies.Read moreRead less
Improved Health Outcomes For People Living With HIV
Funder
National Health and Medical Research Council
Funding Amount
$560,284.00
Summary
Despite the success of antiviral therapy for HIV infection, HIV cannot be cured and treatment is life long. In addition, there are complications in patients on long term antiviral therapy due to impaired immune recovery. This grant will identify strategies to eliminate HIV from latently infected cells that persist in patients on antiviral therapy as well as identify novel ways to improve the immune response to antiviral treatment for patients with HIV infection as well as patients co-infected wi ....Despite the success of antiviral therapy for HIV infection, HIV cannot be cured and treatment is life long. In addition, there are complications in patients on long term antiviral therapy due to impaired immune recovery. This grant will identify strategies to eliminate HIV from latently infected cells that persist in patients on antiviral therapy as well as identify novel ways to improve the immune response to antiviral treatment for patients with HIV infection as well as patients co-infected with hepatitis B virus (HBV)Read moreRead less
Translational Research On Malignant Pleural Effusion And Pleural Infection
Funder
National Health and Medical Research Council
Funding Amount
$487,891.00
Summary
I am a leading researcher in pleural effusions (fluid build-up in the chest) from cancer and infection. I run a multicentre clinical trial team to answer important questions directly relevant to patient care, as well as a lab research group with proven record of discovery new treatment targets. This fellowship will capitalize on platforms I have built and determine best approach to remove effusions, understand etiologic roles of the fluid ultimately to find ways to stop fluid from forming.
Stephen Stick Practitioner Fellowship In Paediatric Respiratory Medicine
Funder
National Health and Medical Research Council
Funding Amount
$542,272.00
Summary
Fellowship will facilitate the further study of mechanisms of chronic childhood respiratory disease and strategies for intervention to reduce morbidity and improve quality of life for patients and families.
The Future Of HIV Care - Long Term Remission And Eliminating Co-morbidities
Funder
National Health and Medical Research Council
Funding Amount
$577,189.00
Summary
Despite the great successes in antiretroviral therapy (ART) in reducing HIV-associated mortality, treatment is life long and there is no cure. The major barrier to a cure for HIV is the persistence of long lived latently infected cells on ART. Over the next five years I will discover, develop, optimise and evaluate novel interventions to eliminate latently infected cells, long lived infected cells in the liver and enhance HIV-specific immunity through immunotherapy.
Generating And Applying Clinical Research To Improve The Outcomes Of Neonatal Intensive Care
Funder
National Health and Medical Research Council
Funding Amount
$568,892.00
Summary
Birth is a complex process and sometimes babies require help to make the transition to independent life. Professor Peter Davis is conducting research into how best to support this transition. This involves helping the lungs to work efficiently and supporting the changes in circulation of the blood to the brain and to the rest of the body. His work aims to quickly identify babies who need help and then provide better treatments to make sure they have the best chance of a healthy life.
Immunopathogenesis And Manipulation Of The HIV Reservoir
Funder
National Health and Medical Research Council
Funding Amount
$494,732.00
Summary
Kelleher is a Clinical immunologist with a globally recognised, sustained track record of translational research which has impacted both on our understanding of HIV immunopathogenesis and on the way HIV infection is treated. He will conduct a series of studies that encompass basic scientific techniques through to pivotal pre-clinical and clinical studies that will provide a pathway towards control of HIV-infection without daily therapy.
The renewal of my Practitioner Fellowship will continue to facilitate an expanding program of epidemiological and clinical research in viral hepatitis, with a primary focus on hepatitis C. New directions will include development of international clinical cohort and trials networks, particularly to characterise the natural history of early hepatitis C infection and evaluate hepatitis C therapuetic strategies for injecting drug users.
Hepatitis C Vaccines: Preclinical To Clinical Development
Funder
National Health and Medical Research Council
Funding Amount
$474,244.00
Summary
Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the p ....Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the prevention of hepatitis C infection.Read moreRead less